Rumi secures option to advance experimental fragile X treatment
Therapy originally developed by Enthorin Therapeutics to be renamed RTX-7340
Written by |
An experimental treatment for fragile X syndrome will be advanced toward clinical testing under a new licensing agreement between two U.S.-based biopharmaceutical companies. (Photo from iStock)
An experimental treatment for fragile X syndrome that has shown promise in easing cognitive and behavioral issues in animal models of the disease will be advanced toward clinical testing under a new licensing agreement between two U.S.-based biopharmaceutical companies.
Under the agreement, New York-based Rumi Therapeutics has obtained an option to license the therapy candidate ENT-7340 from California-based Enthorin Therapeutics. Rumi will take over development of the therapy, to be renamed RTX-7340, and work toward bringing it into clinical testing. Enthorin will provide scientific and technical support during the early stages of development.
“With RTX-7340, we are combining [a clinical trial-ready] asset with insights generated through Rumi Scientific’s human organoid platform and a development strategy centered on translation to patients,” Ignacio Muñoz-Sanjuán, PhD, Rumi’s CEO, said in a company press release. “Fragile X is our initial focus, with opportunities to investigate the relevance of this biology across other neurodevelopmental disorders.”
Organoids are miniature, lab-grown structures that mimic certain features of human organs, including the brain.
In a separate company press release, Marco Peters, PhD, co-founder and chief scientific officer of Enthorin, said: “We are excited about this agreement and look forward to supporting Rumi during the initial development phase as they advance the program toward clinical development.”
Rumi will make an upfront payment and pay an additional fee if it exercises its option to license the therapy. Enthorin could also receive further payments if development, regulatory, and commercial goals are met, plus royalties on future sales. Financial details were not disclosed.
RTX-7340 designed to block key enzyme
Fragile X is caused by mutations in the FMR1 gene that lead to little or no production of FMRP, a protein that helps regulate the production of several proteins involved in nerve cell communication. Without enough FMRP, brain development and function are disrupted, leading to symptoms such as learning difficulties, anxiety, hyperactivity, social avoidance, and sensitivity to sounds, lights, or other sensory information.
RTX-7340 works by blocking phosphodiesterase 2A (PDE2A), an enzyme found in brain circuits involved in thinking, sensory processing, and behavior and whose levels are increased in fragile X animal models.
PDE2A breaks down cAMP and cGMP, two chemical messengers known as cyclic nucleotides. These help regulate nerve cell activity and synaptic plasticity — the ability of connections between nerve cells to strengthen or weaken in response to new information.
By suppressing PDE2A, RTX-7340 is designed to increase cAMP and cGMP signaling, potentially helping to restore communication between nerve cells and ease fragile X symptoms.
[RTX-7340] represents years of discovery and development work aimed at translating the biology of PDE2 [suppression] into effective therapeutics for the treatment of neurodevelopmental disorders such as Fragile X.
In preclinical studies involving mouse models of Fragile X, the experimental therapy was shown to improve synaptic plasticity, ease cognitive and autism-related behavioral abnormalities, and help correct abnormal brain-wave patterns.
RTX-7340 “represents years of discovery and development work aimed at translating the biology of PDE2 [suppression] into effective therapeutics for the treatment of neurodevelopmental disorders such as Fragile X,” Peters said.
The candidate’s development was supported by the FRAXA Research Foundation, a U.S.-based nonprofit dedicated to advance fragile X care.
“FRAXA has long supported research aimed at understanding how altered cellular signaling contributes to Fragile X syndrome and how those discoveries can be translated into treatments,” said Michael Tranfaglia, MD, FRAXA’s medical director and cofounder. “Cyclic nucleotide signaling has emerged as an important part of that biology, and we are pleased to have supported Enthorin’s work in this area.”
Rumi to explore therapy’s potential in other disorders
RTX-7340 is considered investigational new drug (IND)-ready. This means the experimental therapy has reached an advanced preclinical development stage, with enough information to support an IND application to the U.S. Food and Drug Administration seeking to begin testing the therapy in people.
“The advancement of RTX-7340 toward clinical development is an encouraging next step in translating this science into potential treatments for people with Fragile X,” Tranfaglia said.
Rumi plans to draw on technology developed by its sister company, Rumi Scientific, which uses human organoids to study diseases and potential treatments. The technology will allow researchers to further investigate how RTX-7340 works in human cells and explore its potential in fragile X and other neurodevelopmental disorders.
The company also plans to identify measures of brain activity that could be used in future clinical trials. These would help researchers assess whether RTX-7340 reaches its target, produces measurable changes in brain function, and whether those changes are associated with lessening of symptoms.
“A central challenge in Fragile X drug development is connecting a treatment’s effects on disease biology with outcomes that matter to patients,” said Craig Ericksson, the director of Cincinnati Children’s Hospital’s Fragile X Syndrome Research and Treatment Center. “Combining human organoid research with neurophysiological measures creates an opportunity to build that connection more deliberately. A PDE2 program developed around this framework could help us evaluate both whether the drug affects relevant brain function and whether those effects translate into clinical benefit.”
Leave a comment
Fill in the required fields to post. Your email address will not be published.